PET and MR imaging in prostate cancer

The current risk assessment of prostate cancer (PC) relies on histopathological samples from biopsies and clinical variables such as prostate-specific antigen (PSA). However, this comes with uncertainties and in some cases it can be challenging to separate patients who would benefit from radical treatment and those who would not. The risk assessment tools for PC need to be improved and preferably developed into predictive markers. Medical imaging using positron emission tomography (PET) and magnetic resonance imaging (MRI) are potential diagnostic modalities for achieving such improvements. Both PET and MRI have several clinical applications in PC already and are increasingly being incorporated at different steps in the clinical management. For example, MRI is used to guide targeted biopsies, and also as a guide during planning of external beam radiotherapy treatments with focal boosting of the macroscopic visible tumour. However, more precise and individual treatment strategies demand verification of both the characterisation regarding aggressiveness and spatial distribution of the disease. To evaluate the performance of PET and MRI in detection of biochemical recurrent PC after radical prostatectomy, a systematic literature review was conducted (study I). The results of this systematic review indicated that there is a large variety of available imaging methods for PC being used for detecting local and/or locoregional recurrence. Many of the included studies were based on evaluation of patients with high PSA levels yielding high sensitivities and specificities. A pooled mean sensitivity was calculated to 84% for multiparametric MRI (mpMRI) and Choline-PET/CT. Methodological variations between and within studies were observed which limited the possibility of performing a meaningful meta-analysis. No publications evaluating radiotracers binding to prostate-specific membrane antigen (PSMA) were included in the review, although the early literature of using PSMA-PET showed much promise. To introduce a PSMA-binding radiotracer to the clinical management of PC at Umeå University Hospital a clinical trial was performed with the aim to investigate the clinical performance of the radiotracer [ 68 Ga]PSMA-11. In this clinical trial we aimed to both evaluate the diagnostic performance and the safety of the radiotracer. To evaluate the safety, regarding radiation-exposure, absorbed organ doses as well as the effective dose were calculated in a cohort of six low-ris